YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024

Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr

he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business

Marksans Q3 FY24 revenue up 22% at Rs 586 Cr

Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%

Lord's Mark Industries files patent for bio-chemistry reagents; Targets revenue of Rs. 200 Cr

These re-agent and diagnostic test kits come with 99.7% accuracy

Max Healthcare announces acquisition of JCI-Accredited 200 bedded Alexis Hospital, Nagpur

The 200 bedded hospital owned & operated by Alexis

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million

Dr Lal Path Labs posts Q3 FY24 consolidated PAT at Rs. 81.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry